Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.23, RTT News reports. The business had revenue of $14.97 million during the quarter. During the same period last year, the firm earned ($0.37) EPS.
Barinthus Biotherapeutics Stock Performance
BRNS stock traded up $0.01 during midday trading on Thursday, reaching $1.49. The company’s stock had a trading volume of 7,485 shares, compared to its average volume of 23,586. The stock has a fifty day simple moving average of $1.29 and a two-hundred day simple moving average of $1.58. Barinthus Biotherapeutics has a 1 year low of $1.11 and a 1 year high of $4.39. The firm has a market capitalization of $58.61 million, a price-to-earnings ratio of -0.89 and a beta of -0.59.
Analysts Set New Price Targets
BRNS has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Barinthus Biotherapeutics in a report on Thursday, September 26th. Alliance Global Partners decreased their price objective on Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating on the stock in a report on Tuesday, August 13th.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
